Ordinary Rebalance | Solactive China Healthcare Disruption Index | Effective Date 1st March 2024
In the ordinary rebalance, the following composition will be implemented effective open 01.03.2024:
| 3SBIO INC |
| AKESO INC |
| ALIBABA HEALTH INFORMATION TECHNOLOGY LTD |
| ALPHAMAB ONCOLOGY |
| CANSINO BIOLOGICS INC |
| CHINA MEDICAL SYSTEM HOLDINGS LTD |
| CHINA RESOURCES PHARMACEUTICAL |
| CSPC PHARMACEUTICAL GROUP LTD |
| GENSCRIPT BIOTECH CORP |
| GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO LTD |
| HANSOH PHARMACEUTICAL GROUP CO |
| HUTCHMED CHINA LTD |
| INNOVENT BIOLOGICS INC |
| JD HEALTH INTERNATIONAL INC |
| KEYMED BIOSCIENCES INC |
| LIVZON PHARMACEUTICAL GROUP INC |
| LUYE PHARMA GROUP LTD |
| PHARMARON BEIJING CO LTD-H |
| REMEGEN CO LTD-H |
| SHANGHAI FOSUN PHARMACEUTICAL GROUP CO LTD |
| SHANGHAI JUNSHI BIOSCIENCES CO LTD |
| SHANGHAI MICROPORT MEDBOT GR |
| SHANGHAI PHARMACEUTICALS HOLDING CO LTD-H |
| SIMCERE PHARMACEUTICAL GROUP |
| SINO BIOPHARMACEUTICAL LTD ORD |
| SKB BIO-B ORD H |
| WUXI APPTEC CO LTD |
| WUXI BIOLOGICS CAYMAN INC |
| YICHANG HEC CHANGJIANG PHA-H |
| ZAI LAB LTD |